The BLA seeking accelerated approval for patritumab deruxtecan in previously treated, locally advanced EGFR-mutated NSCLC in ...

The FDA biologics license application for patritumab deruxtecan in EGFR+ NSCLC has been withdrawn following discussions with ...

Findings from HERTHENA-Lung02 showed that the key secondary endpoint of overall survival did not meet statistical significance.

Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn The Biologics ...

Patritumab deruxtecan is a specifically engineered HER3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Daiichi Sankyo and Merck (MRK).

Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic ...

Japan’s Daiichi Sankyo (TYO: 4568) and partner Merck & Co (NYSE: MRK) today revealed that the Biologics License Application ...

The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and ...

Rahway: Daiichi Sankyo and Merck, known as MSD outside of the United States and Canada, have announced that the Biologics ...

Merck and Japan-based Daiichi Sankyo have withdrawn their U.S. application for an experimental lung cancer treatment after it ...